Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1985 1
1986 1
1987 2
1988 1
1989 2
1991 2
1994 4
1995 1
1996 1
2000 1
2001 2
2002 6
2003 5
2004 6
2005 3
2006 5
2007 8
2008 10
2009 11
2010 5
2011 3
2012 4
2013 1
2014 1
2015 3
2016 1
2017 3
2018 3
2019 8
2020 9
2021 12
2022 10
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Tatouage d’amalgame sur les gencives.
Sasaki R, Taneda S, Okamoto T. Sasaki R, et al. Among authors: taneda s. CMAJ. 2023 Oct 16;195(40):E1390-E1391. doi: 10.1503/cmaj.230584-f. CMAJ. 2023. PMID: 37844927 Free PMC article. French. No abstract available.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Among authors: taneda s. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Clinical Trial.
Gingival amalgam tattoo.
Sasaki R, Taneda S, Okamoto T. Sasaki R, et al. Among authors: taneda s. CMAJ. 2023 Aug 21;195(32):E1083-E1084. doi: 10.1503/cmaj.230584. CMAJ. 2023. PMID: 37604524 Free PMC article. No abstract available.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T; SWITCH-SEMA 2 study group. Furusawa S, et al. Among authors: taneda s. Diabetes Obes Metab. 2024 Mar;26(3):961-970. doi: 10.1111/dom.15393. Epub 2023 Dec 11. Diabetes Obes Metab. 2024. PMID: 38073422 Clinical Trial.
PLA2R-positive membranous nephropathy in IgG4-related disease.
Ushio Y, Akihisa T, Karasawa K, Seki M, Kobayashi S, Miyabe Y, Kataoka H, Ito N, Taneda S, Akiyama S, Hebisawa A, Kawano M, Honda K, Hoshino J. Ushio Y, et al. Among authors: taneda s. BMC Nephrol. 2024 Feb 23;25(1):66. doi: 10.1186/s12882-024-03511-3. BMC Nephrol. 2024. PMID: 38395839 Free PMC article.
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H, Takahashi A, Nakamura A, Kurihara H, Takeuchi J, Nagai S, Taneda S, Miya A, Kameda H, Cho KY, Miyoshi H, Atsumi T. Nomoto H, et al. Among authors: taneda s. BMJ Open Diabetes Res Care. 2022 Nov;10(6):e002988. doi: 10.1136/bmjdrc-2022-002988. BMJ Open Diabetes Res Care. 2022. PMID: 36379585 Free PMC article.
129 results